May 22 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of recommending that COVID-19 vaccines for 2025-26 should target newer strains of the JN.1 variant.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.